NEUROONE MEDICAL TECHNOLOGIES Corp — Director's Dealing 2021

Jan 21, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK: 0001500198
Period of Report: 2021-01-15

Reporting Person: BESSER JAMES E (10% Owner)
Reporting Person: FRANK MORGAN C. (10% Owner)
Reporting Person: MANCHESTER MANAGEMENT CO LLC (10% Owner)
Reporting Person: MANCHESTER MANAGEMENT PR, LLC (10% Owner)
Reporting Person: Manchester Explorer, L.P. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	492951	Direct
Common Stock	4750000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant	$1.75	2026-01-15	Common Stock (250000)		Direct
Warrant	$1.75	2026-01-15	Common Stock (4750000)		Indirect

Footnotes

F1: The reported securities and warrants are directly owned by Manchester Explorer, L.P. JEB Partners, L.P and by Morgan C. Frank in his personal capacity. The reported securities and warrants are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P. The reported securities and warrants may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC and by Morgan C. Frank, who serves as a portfolio manager and as a consultant for Manchester Management Company, LLC.

F2: The Reporting Persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of the securities and warrants for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.